insulin secretagogues

Glimeripide - Linagliptin - Mitiglinide - Repaglinide      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAdverse events leading to treatment discontinuationCardiovascular death

diabetes type 2

alogliptin
Seino, 2011      NCTalogliptin -
Seino, 2011     alogliptin -
Bosi , 2011      NCTalogliptin -
Kaku, 2011     alogliptin -
Rosenstock, 2010      NCTalogliptin -
Rosenstock, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
Pratley, 2009      NCTalogliptin -
DeFronzo , 2008      NCTalogliptin -
EXAMINE, 2011        NCTalogliptinplacebonegative-20%
Nauck, 2009      NCTalogliptinplacebo (add on MET)Low risk of bias negative
gliclazide
Ristic, 2006       gliclazidenateglinide (add on MET)Low risk of bias -
Matthews, 2005     gliclazidepioglitazone (add on MET)Low risk of bias -
Khanolkar, 2008     gliclaziderosiglitazone (add on MET) -
glimepiride
Charpentier, 2001     glimepiride monotherapymetforminLow risk of bias -
glimeripide
Study 201 (Goldberg), 1996   glimepirideplaceboLow risk of bias -
Schade, 1998   glimepirideplaceboLow risk of bias -
Rosenstock, 1996   glimepirideplaceboLow risk of bias -
Luis Bautista, 2003   glimepirideplaceboLow risk of bias -
Kaneko, 1993   glimepirideplacebo -
Study 202   glimepirideplacebo -
Riddle, 1994   glimepirideplacebo (add on insulin) -
LEAD-2 (Nauck) Sulf vs pbo, 2009      NCTglimepirideplacebo (add on MET)Low risk of bias -
Charpentier, 2001     glimepirideplacebo (add on MET)Low risk of bias negative
Draeger, 1996     glimepirideglibenclamideLow risk of bias -
Protocol 311   glimepirideglibenclamide -
Charpentier (301F)   glimepiridegliclazide -
Inukai, 2005     glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997   glimepiride odglimepiride bid -
Clark (301), 1997   glimepirideglipizide -
Dills, 1996   glimepirideglyburideLow risk of bias -
glipizide
Goldstein   glipizidecontrol (add on MET) -
Rosenstock, 1993   glipizideglyburide -
Birkeland, 1994   glipizideglyburide -
Birkeland, 1994   glipizideglyburideLow risk of bias -
Simonson, 1997   glipizideplaceboLow risk of bias -
Testa, 1998   glipizideplacebo -
Feinglos, 2005     glipizide GITSplacebo (add on MET)Low risk of bias -
Nauck, 2007     glipizidesitagliptin (add on MET) -
glyburide
Hermann, 1991   glibenclamidec (add on MET) -
DeFronzo, 1995   glyburidec (add on MET)Low risk of bias -
Erle, 1999   glyburidec (add on MET) -
Marre (ass), 2002   glibenclamidecontrol (add on MET)Low risk of bias -
Tosi, 2003   glibenclamidecontrol (add on MET)Low risk of bias -
Blonde, 2002   glyburidecontrol (add on MET)Low risk of bias -
Garber, 2003   glyburidecontrol (add on MET) -
Garber, 2002   glyburideplaceboLow risk of bias -
Vray, 1995   glyburideplaceboLow risk of bias -
Garber, 2006     glibenclamiderosiglitazone (add on MET)Low risk of bias -
linagliptin
Forst, 2010      NCTlinagliptinLow risk of bias -
CAROLINA, 2012      NCTlinagliptinglimepirideLow risk of bias suggesting
Gallwitz, 2012      NCTlinagliptinglimepiride (add on MET)Low risk of bias -
Owens      NCTlinagliptinMetformin + sulfonylurea -
Del Prato      NCTlinagliptinplaceboLow risk of bias -
Taskinen      NCTlinagliptinplacebo (add on MET) -
Gomis, 2011      NCTlinagliptinplacebo (add on pioglitazone) -
Lewin, 2010    NCTlinagliptinplacebo (add on SU)Low risk of bias -
mitiglinide
Gao      NCTmitiglinidenateglinideLow risk of bias -
Kumashiro, 2007     mitiglinideon top insulin glargine -
Kaku, 2009     mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002     nateglinideplaceboLow risk of bias -
Horton, 2000   nateglinideplaceboLow risk of bias -
Hanefeld, 1990   nateglinideplaceboLow risk of bias -
Saloranta, 2002   nateglinideplaceboLow risk of bias -
Mari, 2005   nateglinideplacebo -
Moses, 2001   nateglinideplaceboLow risk of bias -
Goldberg, 1998   repaglinideplaceboLow risk of bias -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Bech, 2003   repaglinideplaceboLow risk of bias -
Li, 2009   nategliniderepaglinide -
Li, 2007   nategliniderepaglinide -
Ristic, 2006       nateglinidegliclazide (add on MET)Low risk of bias -
repaglinide
Moses, 1999     repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999   repaglinideglibenclamideLow risk of bias -
Marbury, 1999   repaglinideglibenclamide -
Wolffenbuttel, 1999   repaglinideglibenclamideLow risk of bias -
Madsbad, 2001   repaglinideglipizideLow risk of bias -
Lund, 2007   repaglinidemetforminLow risk of bias -
Raskin, 2001   repaglinideon top pioglitazone -
Raskin, 2001   repaglinideon top rosiglitazone -
Raskin, 2000   repaglinideon top troglitazone -
Chuang, 1999   repaglinideplacebo -
Goldberg, 1998   repaglinideplaceboExploratory -
Jovanovic, 2000   repaglinideplaceboLow risk of bias -
Landin-Olsson, 1999   repaglinideplacebo (on top bedtime NPH-insulin) -
saxagliptin
Kawamori, 2012        NCTsaxagliptin -
Forst, 2011   Saxagliptin -
Fonseca, 2012      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Yang, 2011      NCTsaxagliptin -
Nowicki, 2011      NCTsaxagliptin -
Göke, 2010     saxagliptin -
Scheen , 2010     saxagliptin -
Stenlöf , 2010     Saxagliptin -
CV181-040      NCTsaxagliptin + glyburideglyburide uptitration -
CV181-085    NCTsaxagliptin plus metformin XR 1500mgmetformin up to 2000mg -
SAVOR-TIMI 53, 2013        NCTsaxagliptinplacebonegative 3%
saxgliptin, renal study   saxagliptinplacebo (add on current treatment) -
CV181-057    NCTsaxagliptinplacebo (add on insulin) -
DeFronzo, 2009      NCTsaxagliptinplacebo (add on MET)negative
Jadzinsky, 2009      NCTsaxagliptinplacebo (add on MET) -
CV181-066    NCTsaxagliptinplacebo (add on MET) -
CV181-080    NCTsaxagliptinplacebo (add on MET) -
Hollander      NCTsaxagliptinplacebo (add on TZD) -
Rosenstock, 2008    NCTsaxagliptinplacebo (monotherapy) -
CV181-011      NCTsaxagliptinplacebo (monotherapy) -
CV181-038    NCTsaxagliptinplacebo (monotherapy) -
CV181-041    NCTsaxagliptinplacebo (monotherapy) -
saxagliptin vs sitagliptin   saxagliptinsitagliptin (add on MET) -
saxagliptin   saxagliptinglipizideLow risk of bias -
sitagliptin
Stafford , 2011      NCTsitagliptin -
Reasner, 2011      NCTsitagliptincontrol (add on MET) -
Arechavaleta, 2011      NCTsitagliptinglimepiride (add on MET)Low risk of bias -
Aschner, 2010      NCTsitagliptin monotherapymetforminLow risk of bias -
Derosa , 2010     sitagliptin+piometformin+pio -
Goldstein, 2007      NCTsitagliptinplacebonegative-26%
Hanefeld, 2007     sitagliptinplacebonegative1%
Scott* (sit vs pbo), 2007     sitagliptin 50mg bid monotherapyplacebonegative207%
Aschner, 2006      NCTsitagliptin monotherapyplacebonegative-4%
Nonaka, 2008      NCTsitagliptin monotherapyplaceboLow risk of bias negative-100%
Raz, 2006     sitagliptin monotherapyplacebonegative-100%
Barzilai, 2011      NCTsitagliptin monotherapyplaceboLow risk of bias -
Mohan , 2009     sitagliptin monotherapyplaceboLow risk of bias -
Chan, 2008     sitagliptin monotherapyplaceboLow risk of bias -
Vilsbøll, 2010      NCTsitagliptinplacebo (add on insulin+/-MET)Low risk of bias -
Charbonnel, 2006      NCTsitagliptinplacebo (add on MET)negative34%
Nauck, 2007          NCTsitagliptinplacebo (add on MET)negative-24%
Scott** (sit vs pbo on top met), 2007     sitagliptinplacebo (add on MET)negative287%
raz, 2008      NCTsitagliptinplacebo (add on MET) -
Rosenstock , 2006      NCTsitagliptinplacebo (add on PIO)Low risk of bias -
Rosenstock (sit on top pio vs pbo), 2006      NCTsitagliptinplacebo (on top PIO)suggesting459%
Hermansen, 2007     sitagliptinplacebo (on-top glimepiride+/- metformine)negative174%
Rigby , 2010     sitagliptinrosiglitazone (add on MET) -
Al Sifri, 2011     sitagliptinSulphonylurea (on top MET) -
Iwamoto , 2010     sitagliptin monotherapyvogliboseLow risk of bias -
Scott* (sit vs glipi), 2007     sitagliptin 50mg bid monotherapyglipizideLow risk of bias -
Goldstein (sit vs met), 2007     sitagliptinmetformin -
Goldstein (sit+met vs met), 2007     sitagliptinmetformin -
Pérez-Monteverde, 2011      NCTsitagliptinpioglitazoneLow risk of bias -
vildagliptin
NCT00101673      NCTvildagliptin -
Pan, 2008      NCTvildagliptin monotherapyacarboseLow risk of bias -
Foley, 2009      NCTvildagliptin monotherapygliclazideLow risk of bias -
Filozof, 2009      NCTvildagliptingliclazide (add on MET)Low risk of bias -
Matthews , 2010     vildagliptinglimepiride (add on MET)Low risk of bias -
CLAF237A 23104    NCTvildagliptin + METMET -
Schweizer, 2009      NCTvildagliptinmetformin -
Mimori, 2006   vildagliptinplacebo -
Scherbaum [2], 2008          NCTvildagliptinplaceboLow risk of bias negative124%
Rosenstock, 2008      NCTvildagliptinplaceboLow risk of bias -
NCT00351832    NCTvildagliptinplacebo -
Dejager [1], 2007      NCTvildagliptin monotherapyplaceboLow risk of bias negative1%
Pi-Sunyer, 2007      NCTvildagliptin monotherapyplaceboLow risk of bias suggesting338%
Pratley, 2006     vildagliptin monotherapyplaceboLow risk of bias negative+Infini%
Ristic, 2005     vildagliptin monotherapyplacebonegative-40%
Foley, 2011      NCTvildagliptin monotherapyplacebo -
Kikuchi, 2009     vildagliptin monotherapyplacebo -
Ahren, 2009    NCTvildagliptin monotherapyplacebo -
Lukashevich , 2011     vildagliptinplacebo (add on current therapy) -
Kikuchi, 2010      NCTvildagliptinplacebo (add on glimepiride)Low risk of bias -
Fonseca, 2007      NCTvildagliptinplacebo (add on insulin)Low risk of bias suggesting850%
Fonseca , 2008     vildagliptinplacebo (add on insulin) -
Ahren, 2004     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2007      NCTvildagliptinplacebo (add on MET)Low risk of bias negative73%
Goodman, 2009     vildagliptinplacebo (add on MET)Low risk of bias negative
Bosi, 2009      NCTvildagliptinplacebo (add on MET) -
NCT00728351    NCTvildagliptinplacebo (add on MET) -
NCT00822211    NCTvildagliptinplacebo (add on MET) -
NCT00494884 (Wollmer)    NCTvildagliptinplacebo (add on MET) -
NCT00396071    NCTvildagliptinplacebo (add on MET) -
Garber, 2008      NCTvildagliptinplacebo (add on SU)Low risk of bias -
Garber, 2007      NCTvildagliptinplacebo (on top pioglitazone)negative25%
Rosenstock, 2009    NCTvildagliptinrosiglitazoneLow risk of bias -
Ferrannini, 2009      NCTvildagliptinSulfonylurea (add on to MET)Low risk of bias suggesting
GALIANT (Blonde), 2009      NCTvildagliptinTZD (add on MET) -
NCT00368134    NCTvildagliptinvoglibose -
Iwamoto, 2010     vildagliptinvogliboseLow risk of bias -
Schweizer, 2007        NCTvildagliptinmetforminnegative-42%
Goke, 2008     vildagliptinmetformin -
Rosenstock** (vilda vs pio), 2007      NCTvildagliptin monotherapypioglitazoneLow risk of bias -
Bolli, 2008        NCTvildagliptinpioglitazone (add on MET)Low risk of bias negative-5%
Rosenstock** (vilda + pio vs pio), 2007      NCTvildagliptinplacebo (add on TZD)Low risk of bias negative-53%
Rosenstock* (vilda vs rosi), 2007        NCTvildagliptinrosiglitazoneLow risk of bias -